Caricamento...
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis have changed the first‐line treatment of people with advanced non‐small cell lung cancer (NSCLC). Single‐agent pembrolizumab (a PD‐1 inhibitor) is currently the standard of care as monotherapy in patients with PD‐L1 expres...
Salvato in:
| Pubblicato in: | Cochrane Database Syst Rev |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley & Sons, Ltd
2021
|
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8092423/ https://ncbi.nlm.nih.gov/pubmed/33930176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013257.pub3 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|